Novel Strategies for Acute Relief and Prevention of Migraine
DOI:
https://doi.org/10.61427/jcpr.v4.i2.2024.125Keywords:
Cefaly, Ditans, Gepants, MigraineAbstract
Migraine is a debilitated disorder that is often under diagnosed in clinical practice. Early detection of migraine leads to outstanding improvements in patients’ quality of life. New researchers had developed the central sensitization and cutaneous allodina in chronic migraine which is helpful in early treatment approach with triptans and other agents in acute migraine episodes. Right now, five agents are accepted by US food and drug administration (FDA) for migraine prevention. They are namely Divalporex sodium, Propranolol, Timolol maleate, Topiramate and Methysergide. For so many years, other medications have been used to prevent migraine with not much more success rate. They are Tricyclic anti depressants, anti epileptic agents, Nonsteroidal anti-inflammatory drugs (NSAIDs), Selective serotonin reuptake inhibitors (SSRIS), Calcium channel blockers and muscle relaxants. Calcitonin gene related peptide antagonist, Ditans, Botulinum toxin type A, Orexin receptor antagonists etc were the recent novel agents in the treatment and management of migraine. These novel agents showed more affect than other medications in the acute and prophylactic management of migraines. They play a pivotal role in the standard care for migraine treatment that will improve the patient quality of life with better outcomes.
Downloads
References
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden and the need for preventive therapy. Neurology. 2007; 68(5): 343-9.
Bigal ME, Walter S, Rapoport AM. Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015; 79(6): 886-95.
Ambrosini A, D'Alessio C, Magis D, Schoenen J. Targeting pericranial nerve branches to treat migraine: Current approaches and perspectives. Cephalalgia. 2015; 35(14):1308-22.
Roberto G, Raschi E, Piccinni C, Conti V, Vignatelli L, D’Alessandro R, De Ponti F,Poluzzi E. Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: systematic review of observational studies. Cephalalgia. 2015; 35(2):118.
CoLucid Pharmaceuticals (2008) Clinical trial number NCT00384774 for “A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine” at ClinicalTrials.gov Jump up. Clinical trial number NCT00883051 for “Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment” at ClinicalTrials.gov.
De Hoon J, Montieth D, Vermeersch S et al. Safety, pharmacokinetics and pharmacodynamics of LY2951742: A monoclonal antibody targeting CGRP. Cephalalgia Int J Headache. 2013; 33(8 suppl): 247-8.
Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter double-blind pilot comparison of onabotulinum-toxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011; 51(1):21-32.
Barbanti P, Grazzi L, Egeo G, Padovan AM, Liebler E, Bussone G. Noninvasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. J Headache Pain. 2015; 16:61.
Boureau F, Kappos L, Schoenen J et al. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract. 2000; 54: 281-6.
Arcioni R, Palmisani S, Mercieri M, Vano V, Tigano S, Smith T, Fiore MR, Al-Kaisy A, Martelletti P. Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: a prospective, open-label, exploratory study. Eur J Pain. 2016; 20(1): 70-8.
Published
How to Cite
Issue
Section
Copyright (c) 2024 M. Sai Ganesh
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Most read articles by the same author(s)
- M. Sai Ganesh, A Comprehensive Review: Recent Advances in the Management of Retinopathy of Prematurity (ROP) , Journal of Clinical and Pharmaceutical Research: JCPR Volume:4/Issue:3 (2024)
.